news
QUZYTTIR™ shows promise in preventing infusion related reactions
Phase II data suggests intravenous QUZYTTIR™ cetirizine hydrochloride can decrease infusion reactions to anti-CD20 antibody treatments and reduce time to discharge after therapy.
List view / Grid view
Therapeutics
news
EMA concludes review of Lilly’s COVID-19 antibody therapies
The human medicines committee decided that there was significant evidence to endorse the use of a combination of bamlanivimab and etesevimab in outpatients at high risk of severe COVID-19.
news
Ivermectin not beneficial to symptom resolution in mild COVID-19 patients
In a trial of over 400 adult patients with mild COVID-19, ivermectin did not significantly improve the time to symptom resolution compared to placebo.
news
Novel biobattery-powered microneedle patch enables delivery of large molecule drugs
The novel microneedle array uses electroosmotic flow and a series of interconnected micropores to deliver large molecules or extract of fluid samples.
news
US closes enrolment in two COVID-19 antibody studies due to futility
The sub-studies evaluating VIR-7831 and BRII-196 with BRII-198 have stopped enrolment based on recommendations from the Data and Safety Monitoring Board.
news
New partnership to explore potential biodefence applications for FX-06
Under a licensing and collaboration agreement, Partner Therapeutics will evaluate whether FX-06 could be used to treat multiple biothreats of interest to the US Government.
news
NIH halts COVID-19 convalescent plasma trial
The trial evaluating COVID-19 convalescent plasma as a treatment for COVID-19 patients with mild to moderate symptoms was stopped due to ineffectiveness.
news
FOR-6219 shows promise in Phase I endometriosis trial
FOR-6219 was found to be safe and well tolerated by healthy pre- and postmenopausal women and did not induce systemic oestrogen deficiency-related side effects.
news
Positive effects of psychedelic microdosing likely due to placebo effect, finds study
The largest placebo-controlled psychedelics study to date concluded that the psychological benefits of microdoses of psychedelics are likely due to the placebo effect.
news
Merck to manufacture Janssen’s COVID-19 vaccine
Merck has entered into multiple agreements to support the expansion of the supply of COVID-19 medicines and vaccines.
news
COVID-19 treatments update: hydroxychloroquine and tocilizumab
Find out what the WHO has to say about the use of hydroxychloroquine in COVID-19 prevention and the results of a severe COVID-19 pneumonia trial with tocilizumab.
news
Tezepelumab significantly reduces exacerbations of severe asthma
In a Phase III trial, tezepelumab was shown to meaningfully reduce annualised asthma exacerbation rates in a range of patients with severe, uncontrolled asthma.
news
EMA recommends six medications for approval in February meeting
The EMA’s committee adopted positive opinions of six medications, including two orphan drugs, and concluded its review of the use of REGN-COV2 – an investigational antibody therapy for COVID-19.
news
Leukine® significantly improves lung function in hospitalised COVID-19 patients
In the trial Leukine® (sargramostim, rhuGM-CSF) improved oxygenation in COVID-19 patients with acute respiratory failure by at least a third in over half of those treated.
news
Treatment for rare Duchenne muscular dystrophy mutation approved by FDA
The FDA conditionally approved Sarepta’s Amondys 45 (casimersen) after interim Phase III results indicated the treatment is reasonably likely to be of clinical benefit.
